JP2000513340A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2000513340A5 JP2000513340A5 JP1998501656A JP50165698A JP2000513340A5 JP 2000513340 A5 JP2000513340 A5 JP 2000513340A5 JP 1998501656 A JP1998501656 A JP 1998501656A JP 50165698 A JP50165698 A JP 50165698A JP 2000513340 A5 JP2000513340 A5 JP 2000513340A5
- Authority
- JP
- Japan
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9612297.3A GB9612297D0 (en) | 1996-06-11 | 1996-06-11 | Medicinal aerosol formulations |
| GB9612297.3 | 1996-06-11 | ||
| PCT/US1997/009471 WO1997047286A1 (en) | 1996-06-11 | 1997-06-02 | Medicinal aerosol formulations of formoterol |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2000513340A JP2000513340A (ja) | 2000-10-10 |
| JP2000513340A5 true JP2000513340A5 (cg-RX-API-DMAC7.html) | 2005-02-10 |
| JP5000793B2 JP5000793B2 (ja) | 2012-08-15 |
Family
ID=10795182
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP50165698A Expired - Lifetime JP5000793B2 (ja) | 1996-06-11 | 1997-06-02 | 医用ホルモテロールエアゾール製剤 |
Country Status (16)
| Country | Link |
|---|---|
| EP (2) | EP1400239A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP5000793B2 (cg-RX-API-DMAC7.html) |
| AR (1) | AR009231A1 (cg-RX-API-DMAC7.html) |
| AT (1) | ATE275940T1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU726382B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2257841C (cg-RX-API-DMAC7.html) |
| DE (1) | DE69730723T2 (cg-RX-API-DMAC7.html) |
| DK (1) | DK0934057T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2229366T3 (cg-RX-API-DMAC7.html) |
| GB (1) | GB9612297D0 (cg-RX-API-DMAC7.html) |
| ID (1) | ID19520A (cg-RX-API-DMAC7.html) |
| NO (1) | NO320403B1 (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ333202A (cg-RX-API-DMAC7.html) |
| PT (1) | PT934057E (cg-RX-API-DMAC7.html) |
| WO (1) | WO1997047286A1 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA974546B (cg-RX-API-DMAC7.html) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6054488A (en) * | 1996-06-11 | 2000-04-25 | 3M Innovative Properties Company | Medicinal aerosol formulations of formoterol |
| GB9616237D0 (en) | 1996-08-01 | 1996-09-11 | Norton Healthcare Ltd | Aerosol formulations |
| US20010031244A1 (en) | 1997-06-13 | 2001-10-18 | Chiesi Farmaceutici S.P.A. | Pharmaceutical aerosol composition |
| US6423298B2 (en) * | 1998-06-18 | 2002-07-23 | Boehringer Ingelheim Pharmaceuticals, Inc. | Pharmaceutical formulations for aerosols with two or more active substances |
| US6451285B2 (en) | 1998-06-19 | 2002-09-17 | Baker Norton Pharmaceuticals, Inc. | Suspension aerosol formulations containing formoterol fumarate and a fluoroalkane propellant |
| DE19847969A1 (de) * | 1998-10-17 | 2000-04-20 | Boehringer Ingelheim Pharma | Lagerfähig flüssige Formulierung mit Formoterol |
| PT1121112E (pt) * | 1998-10-17 | 2002-11-29 | Boehringer Ingelheim Pharma | Concentrado de substancia activa susceptivel de ser conservado com formoterol |
| DZ2947A1 (fr) | 1998-11-25 | 2004-03-15 | Chiesi Farma Spa | Inhalateur à compteur de dose sous pression. |
| IT1303788B1 (it) * | 1998-11-25 | 2001-02-23 | Chiesi Farma Spa | Formulazioni di aerosol medicinali. |
| US6004537A (en) * | 1998-12-18 | 1999-12-21 | Baker Norton Pharmaceuticals, Inc. | Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol |
| US6290930B1 (en) | 1998-12-18 | 2001-09-18 | Baker Norton Pharmaceuticals, Inc. | Pharmaceutical solution aerosol formulations containing fluoroalkanes and budesonide |
| IT1313553B1 (it) | 1999-07-23 | 2002-09-09 | Chiesi Farma Spa | Formulazioni ottimizzate costituite da soluzioni di steroidi dasomministrare per inalazione. |
| IT1317846B1 (it) | 2000-02-22 | 2003-07-15 | Chiesi Farma Spa | Formulazioni contenenti un farmaco anticolinergico per il trattamentodella broncopneumopatia cronica ostruttiva. |
| HRP20021025B1 (hr) | 2000-05-22 | 2013-11-22 | Chiesi Farmaceutici S.P.A. | Formulacije stabilnih farmaceutskih otopina za inhalatore s odmjerenom dozom pod tlakom |
| SE0004750D0 (sv) * | 2000-12-19 | 2000-12-19 | Astrazeneca Ab | Novel formulation |
| US20030055026A1 (en) | 2001-04-17 | 2003-03-20 | Dey L.P. | Formoterol/steroid bronchodilating compositions and methods of use thereof |
| SI1273292T1 (en) | 2001-07-02 | 2004-12-31 | Chiesi Farmaceutici S.P.A. | Optimised formulation of tobramycin for aerosolization |
| AR036358A1 (es) * | 2001-08-28 | 2004-09-01 | Schering Corp | Un inhalador de dosis medidas que contiene una formulacion de suspension en aerosol para inhalacion, un proceso para la produccion de la formulacion, el producto y el uso de una formulacion para la manufactura de un medicamento de asma |
| GB0207899D0 (en) * | 2002-04-05 | 2002-05-15 | 3M Innovative Properties Co | Formoterol and cielesonide aerosol formulations |
| GB0207906D0 (en) * | 2002-04-05 | 2002-05-15 | 3M Innovative Properties Co | Formoterol and mometasone aerosol formulations |
| DE60336602D1 (de) | 2002-08-27 | 2011-05-12 | Schering Corp | Verfahren zur Herstellung von Formulierungen für Inhaliergeräte mit abgemessener Dosis |
| CA2528479A1 (en) | 2003-06-13 | 2004-12-23 | Altana Pharma Ag | Formoterol and ciclesonide combination |
| TWI359675B (en) | 2003-07-10 | 2012-03-11 | Dey L P | Bronchodilating β-agonist compositions |
| WO2005041931A2 (en) * | 2003-10-20 | 2005-05-12 | Schering Corporation | Pharmaceutical aerosol compositions |
| EP1925293A3 (en) * | 2003-10-20 | 2010-01-13 | Schering Corporation | Pharmaceutical aerosol compositions |
| EP1595531A1 (en) | 2004-05-13 | 2005-11-16 | CHIESI FARMACEUTICI S.p.A. | Stable pharmaceutical solution formulations for pressurized metered dose inhalers |
| PL2077830T3 (pl) * | 2006-10-17 | 2013-04-30 | Lithera Inc | Sposoby, kompozycje i formulacje do leczenia orbitopatii tarczycowej |
| KR20170070274A (ko) | 2009-05-29 | 2017-06-21 | 펄 테라퓨틱스 인코포레이티드 | 지속형 무스카린 안타고니스트 및 지속형 ｂ₂아드레날린 수용체 아고니스트의 폐 전달용 조성물, 및 연관된 방법 및 시스템 |
| US8815258B2 (en) | 2009-05-29 | 2014-08-26 | Pearl Therapeutics, Inc. | Compositions, methods and systems for respiratory delivery of two or more active agents |
| DK2727582T3 (en) | 2009-10-02 | 2016-05-17 | Chiesi Farma Spa | Pharmaceutical aerosol formulations of formoterol and beclomethasone dipropionate |
| JP6454323B2 (ja) | 2013-03-15 | 2019-01-16 | パール セラピューティクス，インコーポレイテッド | 粒子状結晶性材料のコンディショニングのための方法及びシステム |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI913899A0 (fi) * | 1989-02-23 | 1991-08-19 | Rorer Int Holdings | Terapeutiska aerosolblandningar. |
| IL97065A (en) * | 1990-02-02 | 1994-01-25 | Fisons Plc | Repellent preparations for aerosol |
| GB9024365D0 (en) * | 1990-11-09 | 1991-01-02 | Glaxo Group Ltd | Medicaments |
| EP0504112A3 (en) * | 1991-03-14 | 1993-04-21 | Ciba-Geigy Ag | Pharmaceutical aerosol formulations |
| HUT67445A (en) * | 1991-06-10 | 1995-04-28 | Schering Corp | Aerosol formulations containing 1,1,1,2-tetrafluorethane |
| ZA924164B (en) * | 1991-06-10 | 1993-02-24 | Schering Corp | Non-chlorofluorocarbon aerosol formulations |
| IL104068A (en) * | 1991-12-12 | 1998-10-30 | Glaxo Group Ltd | Surfactant-free pharmaceutical aerosol formulation comprising 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n- propane as propellant |
| EP0616525B1 (en) * | 1991-12-12 | 1995-09-27 | Glaxo Group Limited | Pharmaceutical aerosol formulation |
| EP0617610B1 (en) * | 1991-12-18 | 1997-03-19 | Minnesota Mining And Manufacturing Company | Suspension aerosol formulations |
| GB9207400D0 (en) * | 1992-04-02 | 1992-05-13 | Smithkline Beecham Plc | Novel use |
| US5354934A (en) * | 1993-02-04 | 1994-10-11 | Amgen Inc. | Pulmonary administration of erythropoietin |
| GB9425160D0 (en) * | 1994-12-10 | 1995-02-08 | Glaxo Group Ltd | Medicaments |
| GB9426252D0 (en) * | 1994-12-24 | 1995-02-22 | Glaxo Group Ltd | Pharmaceutical composition |
-
1996
- 1996-06-11 GB GBGB9612297.3A patent/GB9612297D0/en active Pending
-
1997
- 1997-05-23 ZA ZA974546A patent/ZA974546B/xx unknown
- 1997-06-02 PT PT97929756T patent/PT934057E/pt unknown
- 1997-06-02 EP EP03014565A patent/EP1400239A1/en not_active Withdrawn
- 1997-06-02 NZ NZ333202A patent/NZ333202A/en not_active IP Right Cessation
- 1997-06-02 AT AT97929756T patent/ATE275940T1/de not_active IP Right Cessation
- 1997-06-02 AU AU33739/97A patent/AU726382B2/en not_active Expired
- 1997-06-02 WO PCT/US1997/009471 patent/WO1997047286A1/en not_active Ceased
- 1997-06-02 DK DK97929756T patent/DK0934057T3/da active
- 1997-06-02 ES ES97929756T patent/ES2229366T3/es not_active Expired - Lifetime
- 1997-06-02 EP EP97929756A patent/EP0934057B1/en not_active Expired - Lifetime
- 1997-06-02 CA CA002257841A patent/CA2257841C/en not_active Expired - Lifetime
- 1997-06-02 JP JP50165698A patent/JP5000793B2/ja not_active Expired - Lifetime
- 1997-06-02 DE DE69730723T patent/DE69730723T2/de not_active Expired - Lifetime
- 1997-06-04 AR ARP970102437A patent/AR009231A1/es unknown
- 1997-06-09 ID IDP971970A patent/ID19520A/id unknown
-
1998
- 1998-12-07 NO NO19985720A patent/NO320403B1/no unknown